Business Context and Reporting Period
This Form 8-K is a current report filed by BeiGene, Ltd. on July 28, 2021. The filing primarily addresses the company's progress regarding a proposed public offering of ordinary shares (RMB Shares) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. On July 28, 2021, the company filed a registration application for this offering with the China Securities Regulatory Commission (CSRC), following approval of the listing application by the STAR Market Listing Committee on June 28, 2021.
Key Financial Metrics
The filing references financial data prepared in accordance with PRC GAAP for the years ended December 31, 2018, 2019, and 2020, specifically regarding research and development expenses allocated by key products. It also includes a preliminary range of financial results for the six months ended June 30, 2021, covering total revenue and net loss attributable to the company.
Note: The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the attached Exhibit 99.1 and the Chinese-language Prospectus, which are not part of the text provided for this summary.
Material Changes
- Regulatory Progress: The STAR Market Listing Committee approved the company's listing application on June 28, 2021.
- Registration Filing: On July 28, 2021, the company filed the registration application and an updated prospectus with the CSRC.
- Share Structure: The proposed RMB Shares will not be fungible with the company's ordinary shares listed on the Hong Kong Stock Exchange or its American Depositary Shares listed on the NASDAQ Global Select Market.
- Issuance Cap: The number of RMB Shares to be issued (including over-allotment) will not exceed 132,313,549 ordinary shares, representing no more than 10% of the total issued ordinary shares as of January 7, 2021, plus the RMB Shares to be issued.
Guidance, Outlook, and Risks
Outlook and Conditions: The consummation of the STAR Offering is subject to market conditions and additional regulatory approvals, specifically registration granted by the CSRC. There is no assurance that the offering will materialize or when it may occur.
Risks and Contingencies: The filing highlights several risks, including the possibility that the company will be unable to consummate the offering, that final financial performance data may differ from preliminary data, and uncertainties regarding the efficacy and safety of drug candidates. Additional risks include regulatory actions affecting clinical trials, reliance on third parties for manufacturing, and the impact of the COVID-19 pandemic on operations.
Management Commentary: Management notes that the financial information included in the prospectus is unaudited and prepared under PRC GAAP. The company undertakes no duty to update the forward-looking statements unless required by law.
Investor Verification Checklist
- Verify the specific preliminary revenue and net loss figures for the six months ended June 30, 2021, in Exhibit 99.1.
- Confirm the status of the CSRC registration approval for the STAR Offering.
- Review the detailed breakdown of R&D expenses by product for 2018-2020 in the attached financial information.
- Assess the potential dilution impact of issuing up to 132,313,549 new RMB Shares.
- Monitor for updates on the fungibility status of the new RMB Shares relative to existing ADS and HK shares.